abstract |
This disclosure generally describes modified forms of CD16, genetically modified cells that express modified CD16, and methods involving genetically modified cells. A modified form of CD16 may exhibit at least in part anti-tumor and / or anti-viral activity due to low sensitivity to ADAM17-mediated shedding upon NK cell stimulation. |